Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Oral Health Care for Children and Youth With Developmental Disabilities: Clinical Report
Sarvas, Elise , Webb, Jessica , Landrigan‐Ossar, Mary, Yin, Larry , HEALTH, SECTION ON ORAL, Beyer, Eric L., Brooks, Chevon, Feldman, Lauren , Kimball, C E, Tate, Anupama Rao , Unkel, John H. , Zaborowski, Matt, Crespin, Matt, Moursi, Amr M. , Beskin, Kera , Agrawal, Rishi , Bell, Deanna S. , Foster, Jessica E.A., Fremion, Ellen , Frierson, Sheryl, Melicosta, Michelle, Saunders, Barbara S. , Srivastava, Siddharth , Vargus‐Adams, Jilda , Kuo, Dennis Z. , Brosco, Jeffrey P. , Sadof, Matthew , Ware, Allysa , Yeargin-Allsopp, Marshalyn, Poon, Jennifer, Yeargin-Allsopp, Marshalyn, Kuznetsov, Alexandra , MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Chatterjee, Debnath , Diaz, Christina D. , Drum, Elizabeth T. , Sun, Lena S. , Willer, Brittany L. , Landrigan-Ossar, Mary, Fehr, James J. , Lin, Yuan‐Chi, Riefe, Jennifer, Sarvas, Elise W , HEALTH, SECTION ON ORAL, Karp, Jeffrey M. , Kimball, C. Eve, Sokal‐Gutierrez, Karen , Noritz, Garey H. , Zuckerman, Katharine E. , Weitzman, Carol Cohen , Yeargin-Allsopp, Marshalyn, Yeargin-Allsopp, Marshalyn, MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Long, Justin, Landrigan-Ossar, Mary, Adler, Adam C.

Mayo Clinic

Pediatrics | July 22, 2024 | Volume: 154 | Issue: 2 | Pages: No page available

10.1542/peds.2024-067603 | PMID 39034828 Get It

Oral health is an essential component of overall health for all individuals. The oral health of children and youth with developmental disabilities (CYDD) involves unique characteristics and needs of which pediatricians and pediatric clinicians can be aware. Risk for oral disease in CYDD is multifactorial and includes underlying medical conditions, medications, and ability to participate in preventive oral health care and treatment, and lack of access to providers is common for this population despite being eligible for Medicaid. Pediatric clinicians are uniquely positioned to support the oral health needs of CYDD and their families through the medical home. This clinical report aims to inform pediatric clinicians about the unique oral health needs of CYDD. It provides guidance on assessing caries risk and periodontal status using structured screening instruments; understanding dental trauma, the role of diet and caries risk, trauma prevention, and malocclusion; and providing anticipatory guidance on oral hygiene that includes tooth brushing, use of fluoridated toothpaste, assessing community water fluoridation, advocating for a dental home by 1 year of age, and transition to adult dental care as part of adolescent health care. It also highlights special considerations for dental treatment rendered under sedation or general anesthesia that CYDD may need. Pediatric clinicians can help reduce risk of CYDD developing dental disease by understanding the unique needs of their patients and their barriers to accessing oral health care in their community, communicating with the child’s dental home, and advocating for safe and accessible dental procedures.
Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial
Peris, Ketty , Inocencio, Timothy J. , Stratigos, Alexander , Lewis, Karl D. , Eroglu, Zeynep , Chang, Anne Lynn S. , Ivanescu, Cristina, Fury, Matthew G., Chen, C., Quek, Ruben G.W. , Sekulić, Aleksandar , Inocencio, Timothy J , Sekulic, Aleksander , Chen, Chieh-I

Mayo Clinic

Cancer Medicine | July 20, 2024 | Volume: 13 | Issue: 14 | Pages: No page available

10.1002/cam4.7360 | PMID 39031963 Get It

AbstractBackgroundA phase 2 cemiplimab study (NCT03132636) demonstrated a 24.1% objective response rate in patients diagnosed with metastatic basal cell carcinoma (mBCC) who were not candidates for continued hedgehog inhibitor (HHI) therapy due to intolerance to previous HHI therapy, disease progression while receiving HHI therapy, or having not better than stable disease on HHI therapy after 9 months. Here, health‐related quality of life (QoL) for this patient population is reported.MethodsAdult patients with mBCC were treated with intravenous cemiplimab at a dose of 350 mg every 3 weeks for 5 treatment cycles of 9 weeks/cycle then 4 treatment cycles of 12 weeks/cycle. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life‐Core 30 (QLQ‐C30) and Skindex‐16 questionnaires at baseline and Day 1 of each cycle. Across Cycles 2 to 9, the overall change from baseline was analyzed using a mixed model with repeated measures. Responder analyses determined clinically meaningful improvement or deterioration (changes ≥10 points) or maintenance across all scales.ResultsPatients reported low symptom burden and moderate‐to‐high functioning at baseline. Maintenance for QLQ‐C30 global health status (GHS)/QoL and across all functioning and symptom scales was indicated by overall mean changes from baseline. Clinically meaningful improvement or maintenance was reported at Cycle 2 for GHS/QoL (77%), functioning scales (77% to 86%), and symptom scales (70% to 93%), with similar proportions of improvement or maintenance at Cycles 6 and 9, excluding fatigue. On the Skindex‐16, clinically meaningful improvement or maintenance was reported across the emotional, symptom, and functional subscales, in 76%–88% of patients at Cycle 2, which were generally maintained at Cycles 6 and 9. Overall mean changes from baseline showed maintenance across these subscales.ConclusionsThe majority of patients treated with cemiplimab reported improvement or maintenance in GHS/QoL and functioning while maintaining a low symptom burden.
Outcomes of patients with R/R B-cell NHL and limited (
Saifi, Omran , Breen, William G. , Rule, William G., Stish, Bradley J. , Bansal, Radhika , Hathcock, Matthew , Johnston, Patrick B. , Ansell, Stephen M. , Khurana, Arushi , Ayala, Ernesto , Kharfan‐Dabaja, Mohamed A. , Peterson, Jennifer , Lester, Scott C. , Bansal, Radhika , Paludo, Jonas , Villasboas, Jose Caetano , Wang, Yucai , Moustafa, Muhamad Alhaj , Murthy, Hemant S , Kharfan-Dabaja, Mohamed A , Hoppe, Bradford S , Peterson, Jennifer L , Rosenthal, Allison , Muñoz, Javier , Lin, Yi , Paludo, Jonas , Villasboas, José C. , Wang, Yucai , Iqbal, Madiha , Moustafa, Muhamad Alhaj , Murthy, Hemant S. , Hoppe, Bradford S.

Mayo Clinic

Blood Advances | July 19, 2024 | Volume: 8 | Issue: 18 | Pages: 4877-4885

10.1182/bloodadvances.2024013647 | PMID 39028948 Get It

Abstract Unirradiated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is heightened in individuals with limited/localized disease before CART. This study reports on the outcomes of patients with R/R NHL and limited (<5 involved sites) disease bridged with or without radiotherapy. A multicenter retrospective review of 150 patients with R/R NHL who received CART with <5 disease sites before leukapheresis was performed. Bridging treatment, if any, was administered between leukapheresis and CART infusion. Study end points included relapse-free survival (RFS), event-free survival (EFS), and overall survival. Before CART infusion, 48 patients (32%) received bridging radiotherapy (BRT), and 102 (68%) did not. The median follow-up was 21 months. After CART infusion, BRT patients had higher objective response (92% vs 78%; P = .046) and sustained complete response rates (54% vs 33%; P = .015). Local relapse in sites present before CART was lower in the BRT group (21% vs 46%; P = .003). BRT patients had improved 2-year RFS (53% vs 44%; P = .023) and 2-year EFS (37% vs 34%; P = .039) compared with patients who did not receive BRT. The impact of BRT was most prominent in patients who had ≤2 pre-CART involved disease sites, with 2-year RFS of 62% in patients who received BRT compared with 42% in those who did not (P = .002). BRT before CART for patients with limited (<5 involved disease sites) R/R NHL improves response rate, local control, RFS, and EFS without causing significant toxicities.
Pitanguy Ligament Preservation in Structural Precision Rhinoplasty
Lisiecki, Jeffrey , Chiodo, Michael V., Novak, Matthew , Rohrich, Rod J., Cotofana, Sebastian

Mayo Clinic

Plastic & Reconstructive Surgery | July 19, 2024 | Volume: 155 | Issue: 3 | Pages: 504e-507e

10.1097/prs.0000000000011652 | PMID 39026387 Get It

Summary: The Pitanguy ligament is a crucial structure in nasal tip support and in maintaining the integrity of the soft-tissue envelope of the nose. In this cadaveric study, the authors dissected out the Pitanguy ligament on a series of fresh human cadaver specimens to elucidate the structure of the ligament and its fate in open rhinoplasty. The Pitanguy ligament can act as a tethering force to the nasal tip when reshaping the nasal tip. Release of the Pitanguy ligament alleviated downward tension on the nasal tip, and tip shaping to a more appropriate position demonstrated that this ligament was displaced from its ideal position. In patients seeking rhinoplasty, this structure may require release and reconstruction to successfully alter tip position and avoid supratip deformity.
Subclinical aortic inflammation in patients with polymyalgia rheumatica
Kaymakci, Mahmut , Berry, Gerald J. , Langenfeld, Hannah E., Hanson, Andrew C. , Crowson, Cynthia S. , Bois, Melanie C. , Sato, Yuki , Le, Kevin , Weyand, Cornelia M. , Kaymakci, Mahmut S , Le, Kevin-Phu C , Warrington, Kenneth J , Berry, Gerald J , Schaff, Hartzell V. , Le, Kevin-Phu C, Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | July 18, 2024 | Volume: 63 | Issue: 12 | Pages: 3289-3296

10.1093/rheumatology/keae373 | PMID 39024049 Get It

Abstract Objectives To examine the clinicopathologic features of patients with polymyalgia rheumatica (PMR) who had thoracic aorta repair surgery. Findings were compared with those of a cohort of patients with giant cell arteritis (GCA) requiring thoracic aorta repair. Methods All patients evaluated at Mayo Clinic in Rochester, MN, with Current Procedural Terminology (CPT) codes for thoracic aorta repair surgery between 2000–2021 were identified. All patients were screened for prior PMR diagnosis. Patients with PMR and no signs of GCA were categorized as clinically isolated PMR. The medical records of all patients were manually reviewed, and pathologists re-examined all the aortic tissues. Results Of the 4621 patients with at least one CPT code for thoracic aorta repair surgery, 43 patients were diagnosed with clinically isolated PMR before the surgery. Detailed histopathological examination of the aortic tissues revealed active inflammation in 30/43 (70%) patients after a median (IQR) of 10.0 (4.7–13.3) years from the PMR diagnosis. When compared with aortic tissue from patients with a prior diagnosis of GCA, the aorta of patients with PMR had more severe inflammation (Grade 3: 15/30 [50%] vs 5/34 [15%], P = 0.002). Patients with PMR and thoracic aorta repair may experience a 40% increased risk of mortality compared with the general population, but this did not reach statistical significance (standardized mortality ratio: 1.40; 95% CI: 0.91–2.07). Conclusions Some patients with PMR have subclinical aortic inflammation that is detectable many years after initial diagnosis and may contribute to the development of aortic aneurysm.
Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations
Samadder, N. Jewel , Gay, E. Greer , Lindpere, Vanda , Bublitz, Michelle L. , Bandel, Lorelei A. , Armasu, Sebastian M. , Ferber, Matthew J. , Klee, Eric W. , Larson, Nicholas B. , Kruisselbrink, Teresa , Egan, Jan B. , Kemppainen, Jennifer L., Bidwell, Jessa , McAllister, Tammy M., Walker, T'Nita S., Klint, Margaret A., Presutti, R. John , Summer-Bolster, Jolene M., Gay, Emily , Klee, Eric W , Larson, Nicholas B , Kruisselbrink, Teresa M, Bidwell, Jessa S , Anderson, Jennifer L. , Kunze, Katie L , Golafshar, Michael A. , Presutti, Richard J , Bobo, William V. , Sekulic, Aleksander , Willman, Cheryl , Lazaridis, Konstantinos N , Lindpere, Vanda , Vierkant, Robert A. , Anderson, Jennifer L., Kunze, Katie L. , Klint, Margaret, Willman, Cheryl L. , Lazaridis, Konstantinos N.

Mayo Clinic

JCO Precision Oncology | July 16, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00106 | PMID 39013133 Get It

PURPOSE The autosomal dominant cancer predisposition disorders hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) are genetic conditions for which early identification and intervention have a positive effect on the individual and public health. The goals of this study were to determine whether germline genetic screening using exome sequencing could be used to efficiently identify carriers of HBOC and LS. METHODS Participants were recruited from three geographically and racially diverse sites in the United States (Rochester, MN; Phoenix, AZ; Jacksonville, FL). Participants underwent Exome+ sequencing (Helix Inc, San Mateo, CA) and return of results for specific genetic findings: HBOC ( BRCA1 and BRCA1) and LS ( MLH1, MSH2, MSH6, PMS2, and EPCAM). Chart review was performed to collect demographics and personal and family cancer history. RESULTS To date, 44,306 participants have enrolled in Tapestry. Annotation and interpretation of all variants in genes for HBOC and LS resulted in the identification of 550 carriers (prevalence, 1.24%), which included 387 with HBOC (27.2% BRCA1, 42.8% BRCA2) and 163 with LS (12.3% MSH6, 8.8% PMS2, 4.5% MLH1, 3.8% MSH2, and 0.2% EPCAM). More than half of these participants (52.1%) were newly diagnosed carriers with HBOC and LS. In all, 39.2% of HBOC/LS carriers did not satisfy National Comprehensive Cancer Network (NCCN) criteria for genetic evaluation. NCCN criteria were less commonly met in underrepresented minority populations versus self-reported White race (51.5% v 37.5%, P = .028). CONCLUSION Our results emphasize the need for wider utilization of germline genetic sequencing for enhanced screening and detection of individuals who have LS and HBOC cancer predisposition syndromes.
Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum
Ali, Farwa , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Whitwell, Jennifer L. , Botha, Hugo , Clark, Heather, Jack, Clifford R , Josephs, Keith A , Whitwell, Jennifer , Botha, Hugo , Clark, Heather M. , Machulda, Mary M. , Senjem, Matthew L.

Mayo Clinic

Brain Communications | July 16, 2024 | Volume: 6 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcae233 | PMID 39056025 Get It

Abstract Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy that presents with highly heterogenous clinical syndromes. We perform cross-sectional data-driven discovery of independent patterns of brain atrophy and hypometabolism across the entire PSP spectrum. We then use these patterns to predict specific clinical features and to assess their relationship to phenotypic heterogeneity. We included 111 patients with PSP (60 with Richardson syndrome and 51 with cortical and subcortical variant subtypes). Ninety-one were used as the training set and 20 as a test set. The presence and severity of granular clinical variables such as postural instability, parkinsonism, apraxia and supranuclear gaze palsy were noted. Domains of akinesia, ocular motor impairment, postural instability and cognitive dysfunction as defined by the Movement Disorders Society criteria for PSP were also recorded. Non-negative matrix factorization was used on cross-sectional MRI and fluorodeoxyglucose-positron emission tomography (FDG-PET) scans. Independent models for each as well as a combined model for MRI and FDG-PET were developed and used to predict the granular clinical variables. Both MRI and FDG-PET were better at predicting presence of a symptom than severity, suggesting identification of disease state may be more robust than disease stage. FDG-PET predicted predominantly cortical abnormalities better than MRI such as ideomotor apraxia, apraxia of speech and frontal dysexecutive syndrome. MRI demonstrated prediction of cortical and more so sub-cortical abnormalities, such as parkinsonism. Distinct neuroanatomical foci were predictive in MRI- and FDG-PET-based models. For example, vertical gaze palsy was predicted by midbrain atrophy on MRI, but frontal eye field hypometabolism on FDG-PET. Findings also differed by scale or instrument used. For example, prediction of ocular motor abnormalities using the PSP Saccadic Impairment Scale was stronger than with the Movement Disorders Society Diagnostic criteria for PSP oculomotor impairment designation. Combination of MRI and FDG-PET demonstrated enhanced detection of parkinsonism and frontal syndrome presence and apraxia, cognitive impairment and bradykinesia severity. Both MRI and FDG-PET patterns were able to predict some measures in the test set; however, prediction of global cognition measured by Montreal Cognitive Assessment was the strongest. MRI predictions generalized more robustly to the test set. PSP leads to neurodegeneration in motor, cognitive and ocular motor networks at cortical and subcortical foci, leading to diverse yet overlapping clinical syndromes. To advance understanding of phenotypic heterogeneity in PSP, it is essential to consider data-driven approaches to clinical neuroimaging analyses.
Molecular Analysis of Persistent and Recurrent Barrett's Esophagus in the Setting of Endoscopic Therapy
Kumar, Aarti , Rara, Marianne , Wen, Kwun Wah , Grady, William M., Chak, Amitabh , Iyer, Prasad G. , Rustgi, Anil K. , Rubenstein, Joel H. , Liu, Yue , Kresty, Laura A. , Westerhoff, Maria , Kwon, Richard S. , Wamsteker, Erik, Wang, Tom, Berry, Lynne D. , Shaheen, Nicholas J. , Wang, Kenneth K, Stachler, Matthew D , Yu, Ming , Wang, Timothy C. , Canto, Marcia Irene , Abrams, Julian A

Mayo Clinic

Clinical and Translational Gastroenterology | July 15, 2024 | Volume: 15 | Issue: 8 | Pages: e00751

10.14309/ctg.0000000000000751 | PMID 39007490 Get It

INTRODUCTION: Early neoplastic progression of Barrett's esophagus (BE) is often treated with endoscopic therapy. Although effective, some patients are refractory to therapy or recur after apparent eradication of the BE. The goal of this study was to determine whether genomic alterations within the treated BE may be associated with persistent or recurrent disease. METHODS: We performed DNA sequencing on pre-treatment esophageal samples from 45 patients who were successfully treated by endoscopic therapy and did not recur as well as pre-treatment and post-treatment samples from 40 patients who had persistent neoplasia and 21 patients who had recurrent neoplasia. The genomic alterations were compared between groups. RESULTS: The genomic landscape was similar between all groups. Patients with persistent disease were more likely to have pre-treatment alterations involving the receptor tyrosine kinase pathway ( P = 0.01), amplifications of oncogenes ( P = 0.01), and deletions of tumor suppressor genes ( P = 0.02). These associations were no longer significant after adjusting for patient age and BE length. More than half of patients with persistent (52.5%) or recurrent (57.2%) disease showed pre-treatment and post-treatment samples that shared at least 50% of their driver mutations. DISCUSSION: Pre-treatment samples were genomically similar between those who responded to endoscopic therapy and those who had persistent or recurrent disease, suggesting there is not a strong genomic component to treatment response. Although it was expected to find shared driver mutations in pre-treatment and post-treatment samples in patients with persistent disease, the finding that an equal number of patients with recurrent disease also showed this relation suggests that many recurrences represent undetected minimal residual disease.
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).
Butowski, Nicholas , Fenn, Peter , Clanton, Ryan, Henry, Lenora, Potter, Wyatt, Andresen, Corina, Marcus, Stuart G., Benaim, Ely , Placantonakis, Dimitris G. , Grabowski, Matthew M. , Burns, Terry C. , Marcus, Stuart

Mayo Clinic

Journal of Clinical Oncology | July 11, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS2101-TPS2101

10.1200/jco.2024.42.16_suppl.tps2101 Get It

TPS2101 Background: Recurrent glioblastoma (rGBM) is a lethal brain tumor with no effective therapy and an extremely poor prognosis (median survival 6 to 8 months after first recurrence). Sonodynamic therapy (SDT) is a non-invasive combination treatment that utilizes a drug, aminolevulinic acid HCL (SONALA-001), and a device, the Exablate 4000 Type 2.0, to deliver non-ablative MR-guided focused ultrasound (MRgFUS) to tumor. Preclinical studies have shown that SDT-induced sonoluminescence activates protoporphyrin IX (PpIX), which in turn generates reactive oxygen species that lead to tumor cell death and improved survival in animal glioma models. A first-in-human Phase 0 trial (NCT04559685) indicated that SONALA-001 SDT was well-tolerated and not associated with off-target cellular or radiographic effects, and provided direct evidence of reactive oxygen species formation and targeted tumor cell death in recurrent high-grade glioma (rHGG). Methods: SDT-202 is a Phase 1/2 multicenter, open-label, dose escalation and expansion study (NCT05370508) of 10 mg/kg iv SONALA-001 in combination with MRgFUS for SDT in patients with progressive or recurrent GBM. Treatments take place every 4 weeks. In phase 1, sonication energy escalation utilizes an accelerated titration design with a single subject for dose level 1, followed by cohorts 2 and 3 with 3+3 design for additional dose escalation. SONALA-001 is administered 6 to 12 hours prior to MRgFUS treatment. Once the RP2D is determined, Phase 2 dose expansion will enroll approximately 36 additional subjects to assess safety and efficacy of repeated cycles of SONALA-001 SDT at the optimized RP2D. Endpoints of this study are safety evaluation, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and determination of pharmacokinetic (PK) parameters. The Phase 2 portion will further characterize safety of RP2D along with evaluation of efficacy with PFS6 (mRANO), ORR, CBR, DOR, DOCR, TTR, and OS. Clinical trial information: NCT05370508 .
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
Chien, A. Jo , Wei, Mei , Veer, Laura van 't, Alkhafaji, Silver , Chen, Nan , Borowsky, Alexander D. , Hylton, Nola, Mukhtar, Rita A. , Giridhar, Karthik V. , Olopade, Olufunmilayo I. , Kalinsky, Kevin M. , Vaklavas, Christos , Elias, Anthony , Goetz, Matthew P. , Rugo, Hope S. , Symmans, W. Fraser , Swigart, Lamorna Brown , Onishi, Natsuko , Yee, Douglas , Esserman, Laura J.

Mayo Clinic

Journal of Clinical Oncology | July 11, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 601-601

10.1200/jco.2024.42.16_suppl.601 Get It

601 Background: EOP is an I-SPY2 neoadjuvant sub-study designed to test the tolerability and impact of novel endocrine-based strategies in stage 2/3 BC pts predicted to have lower benefit from chemotherapy. Amcenestrant (A) is an oral selective estrogen receptor degrader (SERD) with activity in hormone receptor positive (HR+) HER2- metastatic BC. Methods: EOP eligibility included pts screened for the main I-SPY2 trial with HR+ HER2-, MammaPrint (MP) low risk Stage 2/3 BC. Pts with MP High risk tumor signatures were eligible if clinically node-negative (cN-). Pts were stratified by SET index and menopausal status. Pts were randomized to 3 arms: A 200 mg qd (A), A + abemaciclib 150 mg bid (AA), A + letrozole 2.5 mg qd (AL). Premenopausal pts received concurrent ovarian function suppression. Treatment was for 6 mos followed by surgery. Baseline (BL) and 3-wk biopsies were performed. Breast MRIs were conducted at BL (T0), 3 wks (T1), 12 wks (T2), 6 mos (T3). The primary endpoint was feasibility, defined as >75% of pts completing >75% study therapy. Results: Between May 2021 and Aug 2022, 74 pts were randomized: 31 A, 21 AA, 22 AL. Median age 50 years, 54% premenopausal, 38% clinically node-positive (cN+). 41% pts had ductal, 38% lobular, 11% mixed ductal/lobular histology. Mean BL tumor Ki67 (central testing) was 16.9%, 88% MP low, 76% SET index Hi. Pt and tumor characteristics were balanced across the 3 arms. Treatment in all 3 arms was feasible with 95% of pts completing >75% study therapy. Most common AEs include grade 1-2 hot flashes (69%) and fatigue (66%). Grade 3 AEs include neutropenia (2 pts) and diarrhea (1 pt) in AA. Table summarizes key response endpoints, which were similar between pre- and postmenopausal pts. Of 28 cN+ pts, 2 (7%) were pathologically node-negative (pN-). Mean MRI Functional Tumor Volume (cc) change between T0->T1, T1->T2, T2->T3, T0->T3 was -6.06 (-34.2%), -3.55 (-29.2%), -0.829 (-20.1%), -11.3 (-68.4%), respectively, similar across arms (p=0.396).ctDNA was detected in 10/59 (17%) pts at T0. ctDNA became undetectable in 6 pts, decreased in 4 pts, and went from ctDNA undetectable at baseline to detectable at T3 in 2 pts. Conclusions: Six months of neoadjuvant endocrine therapy (NET) with the oral SERD amcenestrant is feasible, well-tolerated, and demonstrates anti-proliferative and anti-tumor activity in pre- and postmenopausal pts. NET provides a rich platform for biomarker discovery and investigating response to endocrine therapy. Clinical trial information: NCT01042379 . [Table: see text]